Terazosin Hydrochloride
Product Images NDC 67544-564

9 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 67544-564). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2mg (67544 562)

Bottle Label 2mg (67544 562)
Packaging label for Terazosin HCl 2mg capsules, containing 120 capsules. The label includes storage instructions to keep the product between 20-25 degrees Celsius and dispense in a tight light-resistant container. It is manufactured by Jubilant Cadista Pharmaceuticals Inc, Salisbury, MD, and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. The label also states the product is RX only and features barcodes and batch/expiration date fields.*
FDA Label Image

Bottle Label 5mg (67544 563)

Bottle Label 5mg (67544 563)
Label for Terazosin hydrochloride 5 mg capsules, 60 count. The label includes storage instructions to keep between 20-25 degrees Celsius and to dispense in a tight light-resistant container. It states the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC, originally manufactured by Jubilant Cadista Pharmaceuticals Inc, Salisbury, MD. The label features barcodes and notes the product is prescription only.*
FDA Label Image

Bottle Label 10mg (67544 564)

Bottle Label 10mg (67544 564)
Label for Terazosin HCl 10 mg capsules, containing 180 capsules per container. The label indicates the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC. It includes storage instructions between 20-25°C and states the manufacturer as Jubilant Cadista Pharmaceuticals Inc. The label includes an NDC number 67544-0564-80 and notes the product is RX only.*
FDA Label Image

Bottle Label 1mg (67544 581)

Bottle Label 1mg (67544 581)
Packaging label for Terazosin hydrochloride 1 mg capsules, containing 30 capsules. The label includes the NDC number 67544-0581-30 and indicates the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC. It provides storage instructions and warns to keep the medication out of reach of children. The label states the product is for RX only and lists Jubilant Cadista Pharmaceuticals Inc as the original manufacturer.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)
Chemical structure of Terazosin hydrochloride showing the arrangement of rings, nitrogen atoms, and functional groups including a quinazoline ring, piperazine ring, and a tetrahydrofuran moiety with associated hydrochloride component.*
FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

Figure 1 (Terazosin Hydrochloride Capsules 2)
This image contains two line graphs comparing Terazosin hydrochloride and placebo effects over 3 months. The left graph shows the mean change in total symptom score from baseline, with Terazosin demonstrating a greater decrease than placebo. The right graph shows the mean increase in peak flow rate (mL/sec) from baseline, where Terazosin exhibits a higher increase compared to placebo. Both graphs include sample sizes (N) for each group and markers indicating statistical significance.*
FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

Figure 2 (Terazosin Hydrochloride Capsules 3)
A line graph depicting the mean change from baseline over a 30-month period. The x-axis represents time in months, and the y-axis shows mean change values. Data points are connected with a line, and several points are marked with asterisks indicating statistical significance. The graph appears to track treatment effects or measurements over time related to Terazosin hydrochloride.*
FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

Figure 3 (Terazosin Hydrochloride Capsules 4)
A line chart depicting mean change from baseline (mL/sec) over a 30-month period, with data points at various months. The graph shows increasing mean change with marked statistical significance at specific time points, indicated by asterisks. Error bars represent variability around the means.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.